MediPharm Labs Revenue Growth is Just Getting Started

Equity Research Healthcare – Cannabis | April 05, 2019
Patrick Smith | Analyst | Ubika Research Patrick@UbikaResearch.com | (647) 444-5506
Christopher Bednarz | Associate | Chris.B@UbikaResearch.com | (416) 558-5548

MediPharm Labs Corp.’s (TSXV:LABS) $10 million in revenue is already ahead of multiple, Canada-based $1B+ market cap cultivators, says Ubika Alpha

MediPharm Labs Corp. TSXV:LABS

(Currency is C$, unless noted otherwise)

Last Price $3.62

52 Week High $3.92

Current Share Price % 52-week high 92.3%

52 Week Low $0.91

Current Share Price % 52-week low397.8%

30-Day Average Daily Volume820.0K

30-Day VWAP$3.18

Company Headquarters Barrie, ON, Canada

Company Website www.medipharmlabs.com

Management Team

Patrick McCutcheon President & CEO

Christopher Hobbs CFO

David MayersCOO

Sybil Taylor CMO

Ahmed ShehataGeneral Counsel

MAJOR SHAREHOLDERS

Management and Insiders (19.4%)

Capitalization Basic Diluted
Shares Outstanding (M) 97.5M 131.6M
Market Capitalization ($M) C$353.0
Enterprise Value ($M) $348.6
Cash Balance ($M) $6.4
Total Debt ($M) $2.0
Relative Valuation EV/Revenue 2019E EV/Revenue 2020E
MediPharm* 4.9x 3.3x
CAN-Based Major Cultivators 42.5x 12.6x
CAN-US Based Operations 9.3x 4.6x

Figure 1: Quarterly Results

www.stockcharts.com

Q4/18 RESULTS: $10M IN REVENUE - JUST GETTING STARTED

Solid start for MediPharm shows a bright future. On April 3, MediPharm released 2018 financials, which beat our estimates driven by higher-than-anticipated margins, slightly offset by lower-than-expected revenue. Revenue and margins came in at $10.2M and $4.0M compared to our estimates of $12.0M and $2.0M, respectively. Expanded margins drove adj. EBITDA higher than we expected, coming in at $2.1M vs. our estimate for -$0.1M (Figure 1). EPS missed our estimate; however, this was due primarily to a one-time transaction fee of $4.2M related to the RTO in October 2018, and to a slight degree, higher-than-expected marketing & G&A. We highlight that the Company also built $9.4M in inventory in addition to the $10M in sales.

RECENT HIGHLIGHTS

  • $10M in revenue is already ahead of multiple, Canada-based $1B+ market cap cultivators. We highlight that MediPharm has only had its sales license since March 29, 2018, and that it already surpassed several significant players in the space (first company to receive an oil license without being a cultivator). For comparison, as of the last-reported quarters, Cronos Group (TSX:CRON, $24.28 | N/R) (Q4/18), CannTrust (TSX:TRST, $10.28 | N/R) (Q4/18), TGOD (TSX:TGOD, $4.70 | N/R) (Q4/18), and HEXO (TSX:HEXO, $8.89 | N/R) (Q1/19), reported revenues of $5.6M, $16.2M, $1.8M, and $13.2M, respectively. We highlight that HEXO’s financials are unique because it includes three months of full recreational sales. For reference, the market caps of these highlighted companies are $7.9B, $1.0B, $1.2B, and $1.8B, respectively. In comparison, the eight publicly listed processors, excluding Curaleaf, have an average market cap of $125M.
  • Canadian extraction efforts need more than what MediPharm can handle – there remains room for many players. Beyond MediPharm’s current capacity of 150,000 kg of dry cannabis per year(planned capacity expected to be 250,000 kg this year), due primarily, in our opinion, to a lack of processing technology and know-how in Canada, we believe there is ample room for other processors in the Canadian space to take market share. Of the eight publicly-listed processors, we believe only five are operating. In our view, within the next one to two-year time frame, there will be a significant revaluation of these companies and that the large Canadian operators will have to either 1) contract these processors to assist with excess biomass or; 2) target for M&A purposes.

VALUATION

Extraction companies are undervalued compared with Canadian cultivators and U.S. multi-state operators. Based on our preliminary estimates, the Company trades at 4.9x and 3.3x, 2019E & 2020E revenue multiples, compared with Canadian majors and U.S.-based peer companies, which trade at a consensus average of 42.5x, and 9.3x for 2019E, 12.6x and 4.6x for 2020E, respectively. On an EBITDA basis, the Company trades at 19.6x and 13.1x 2019E & 2020E multiples, compared with U.S.-based peer companies, which trade at 35.6x and 15.3x, respectively. We believe this gap will close as the market realizes the significant value potential of extractionbased business in Canada.

To read our full disclosure, please click on the button below:

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.